Sudeepta Aggarwal

All India Institute of Medical Sciences — India

Immunology and Microbiology · Life Sciences

27h-index11.1kcitations64works0.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immune Cell Function and Interaction(10), Diabetes Management and Research(9), Diabetes and associated disorders(9), Pancreatic function and diabetes(6), Psoriasis: Treatment and Pathogenesis(5)

Publications64 total

Autonomous UAV Navigation and Mapping for Accurate Fruit Detection and Counting in Controlled Environments: Simulation and Real-World Validation
2025
Expanding Epidemiology: A Case of Pulmonary Disease Caused by <i>Acrophialophora angustiphialis</i>
Open Forum Infectious Diseases·2025Open Access
Efficacy of Nigella sativa seed oil against psychophysical stress induced irritable bowel syndrome and anxiety-like symptoms in Wistar rats
Psychopharmacology·2024· 3 cited
LB944 The efficacy and safety of multiple dose levels of the PDE4 inhibitor PF-07038124 in participants 12 years and older with mild-to-moderate atopic dermatitis and mild-to-severe plaque psoriasis
Journal of Investigative Dermatology·2024
2626. Natural History of RSV Infection in Outpatient Episodes Among Adults in the United States using an EHR Data Source by COVID-19 Era
Open Forum Infectious Diseases·2023Open Access
Effect of Hepatic Impairment on the Pharmacokinetics of Nirmatrelvir/Ritonavir, the First Oral Protease Inhibitor for the Treatment of COVID‐19
The Journal of Clinical Pharmacology·2023· 4 citedOpen Access
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Intravenous Infusions of PF-07304814 (Lufotrelvir) in Participants Hospitalized With COVID-19
Open Forum Infectious Diseases·2023· 10 citedOpen Access
Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study
British Journal of Dermatology·2023· 29 cited
Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study
British Journal of Dermatology·2022· 60 citedOpen Access
ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials
Nature Medicine·2021· 207 cited
Co-administration of PF-05221304 and PF-06865571 delivers robust whole liver fat reduction and mitigation of acetyl-coa carboxilase inhibitor induced hypertriglyceridemia in patients with NAFLD
Journal of Hepatology·2020· 5 citedOpen Access
RSSDI consensus recommendations on insulin therapy in the management of diabetes
International Journal of Diabetes in Developing Countries·2019· 12 cited
PND12 CLINICAL EFFICACY OF VALBENAZINE AND DEUTETRABENAZINE FOR THE TREATMENT OF TARDIVE DYSKINESIA: INDIRECT TREATMENT COMPARISON OF RANDOMIZED CONTROLLED TRIALS
Value in Health·2019
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomized, double-blind, placebo-controlled phase 2 trial
2015
Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes
eScholarship (California Digital Library)·2014Open Access
Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial
2014· 2 cited
Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial.
2013
Targeting effector memory T cells with alefacept in new onset type 1 diabetes: 12 month results from the T1DAL study
PMC·2013
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial
The Lancet Diabetes & Endocrinology·2013· 201 citedOpen Access
Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial
The Lancet Diabetes & Endocrinology·2013· 142 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Sudhir Gupta(13), Austin Gurney(5), Mario R. Ehlers(5), Deborah Phippard(5), Sudhir Gupta(5), Chanderdeep Tandon(5), R. K. Jethi(5), Stephen E. Gitelman(4), Carla J. Greenbaum(4), Jeffrey A. Bluestone(4), Mehdi Forouzandeh(4), Ming-Hong Xie(3), Jessica Foster(3), Peter A. Gottlieb(3), Lynette Keyes-Elstein(3), Peter H. Sayre(3), James McNamara(3), S Gollapudi(3), Arthur Bergman(3), Sastry Gollapudi(3)